Hongwei Lv

3.0k total citations · 2 hit papers
30 papers, 2.1k citations indexed

About

Hongwei Lv is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Hongwei Lv has authored 30 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 10 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Hongwei Lv's work include Cancer Cells and Metastasis (6 papers), MicroRNA in disease regulation (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Hongwei Lv is often cited by papers focused on Cancer Cells and Metastasis (6 papers), MicroRNA in disease regulation (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Hongwei Lv collaborates with scholars based in China, Israel and South Korea. Hongwei Lv's co-authors include Guishuai Lv, Hongyang Wang, Wen Yang, Tian Fang, Changzheng Wang, Qin Han, Liang Tang, Shanhua Tang, Linna Guo and Le‐Xing Yu and has published in prestigious journals such as Nature Communications, Cell Metabolism and Science Advances.

In The Last Decade

Hongwei Lv

28 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer

2018 779 citations Tian Fang, Hongwei Lv et al. Nature Communications profile →
TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer

2024 62 citations Hongwei Lv, Guishuai Lv et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hongwei Lv China	16	1.2k	883	332	312	281	30	2.1k
Hua Wu China	30	1.3k 1.0×	594 0.7×	543 1.6×	299 1.0×	164 0.6×	80	2.5k
Pingwei Xu China	20	1.1k 0.9×	618 0.7×	366 1.1×	451 1.4×	511 1.8×	23	2.1k
Yugang Wang China	24	1.1k 0.9×	680 0.8×	307 0.9×	133 0.4×	231 0.8×	43	1.8k
Shourong Wu China	26	1.4k 1.1×	510 0.6×	303 0.9×	353 1.1×	156 0.6×	65	2.2k
Fei Lu China	25	1.5k 1.2×	496 0.6×	334 1.0×	223 0.7×	243 0.9×	96	2.2k
Noritaka Ohga Japan	30	1.9k 1.5×	949 1.1×	745 2.2×	333 1.1×	318 1.1×	84	2.8k
Aiping Luo China	29	1.8k 1.5×	998 1.1×	598 1.8×	159 0.5×	296 1.1×	66	2.5k
Yu Guo China	28	1.1k 0.9×	636 0.7×	423 1.3×	427 1.4×	335 1.2×	91	2.3k
Caiping Ren China	31	1.7k 1.4×	896 1.0×	543 1.6×	128 0.4×	281 1.0×	116	2.6k
Constantinos M. Mikelis United States	26	1.3k 1.0×	415 0.5×	453 1.4×	142 0.5×	297 1.1×	75	2.2k

Countries citing papers authored by Hongwei Lv

Since Specialization

Citations

This map shows the geographic impact of Hongwei Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongwei Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongwei Lv more than expected).

Fields of papers citing papers by Hongwei Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongwei Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongwei Lv. The network helps show where Hongwei Lv may publish in the future.

Co-authorship network of co-authors of Hongwei Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Hongwei Lv. A scholar is included among the top collaborators of Hongwei Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongwei Lv. Hongwei Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lv, Hongwei, Liang Wang, Guishuai Lv, et al.. (2025). Traditional medicine Bazi Bushen potentiates immunosurveillance of senescent liver cancer cells via cGAS-STING signaling activation in macrophages. Cancer Letters. 627. 217544–217544. 1 indexed citations

Liu, Xiaolin, et al.. (2025). Advances in the relationship of immune checkpoint inhibitors and DNA damage repair. Current Research in Translational Medicine. 73(2). 103494–103494. 1 indexed citations

Wang, Shan, Xiaolin Liu, Hongwei Lv, Jing Yu, & Huihui Li. (2024). The detection of circulating tumor cells indicates poor therapeutic efficacy and prognosis in patients with nonsmall cell lung cancer: A systematic review and meta‐analysis. Journal of Evidence-Based Medicine. 17(2). 329–340. 1 indexed citations

Ma, Yue, et al.. (2024). Cancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progression. Frontiers of Medicine. 18(3). 430–445. 2 indexed citations

Lv, Hongwei, Guishuai Lv, Wei Xiang, et al.. (2024). TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer. Nature Communications. 15(1). 6–6. 62 indexed citations breakdown →

Lv, Hongwei, Xiaoyan Sun, Yue Ma, et al.. (2023). Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation. Science Advances. 9(49). eadi2465–eadi2465. 86 indexed citations

Chen, Enli, et al.. (2023). The role of fatty acid desaturase 2 in multiple tumor types revealed by bulk and single-cell transcriptomes. Lipids in Health and Disease. 22(1). 25–25. 4 indexed citations

Chen, Zhaoxin, et al.. (2022). LIPG is a novel prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma. Journal of Clinical Laboratory Analysis. 37(1). e24824–e24824. 4 indexed citations

Lv, Hongwei, et al.. (2021). SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner. Translational Oncology. 14(6). 101075–101075. 11 indexed citations

10.

Lv, Hongwei, et al.. (2020). Moisture-proof seal optical fiber connector. Guangdian gongcheng. 47(12). 200067.

11.

Lv, Hongwei, Guishuai Lv, Guo‐Qing Jiang, et al.. (2020). NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metabolism. 33(1). 110–127.e5. 179 indexed citations

12.

Fang, Tian, Hongwei Lv, Guishuai Lv, et al.. (2018). Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nature Communications. 9(1). 191–191. 779 indexed citations breakdown →

13.

Lv, Hongwei, et al.. (2018). Induction therapy for clinical stage T2N0M0 esophageal cancer. Medicine. 97(40). e12651–e12651. 12 indexed citations

14.

Lv, Hongwei, et al.. (2017). Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis. Medicine. 96(26). e7342–e7342. 7 indexed citations

15.

Li, Yin, et al.. (2017). Laparoscopic Heller myotomy is not superior to pneumatic dilation in the management of primary achalasia. Medicine. 96(7). e5525–e5525. 23 indexed citations

16.

Wang, Changzheng, Hongwei Lv, Wen Yang, et al.. (2017). SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts. Cancer Letters. 398. 1–11. 36 indexed citations

17.

Lv, Hongwei, et al.. (2017). Biomaterial stiffness determines stem cell fate. Life Sciences. 178. 42–48. 65 indexed citations

18.

Lv, Guishuai, Yexiong Tan, Hongwei Lv, et al.. (2017). MXR7 facilitates liver cancer metastasis via epithelial-mesenchymal transition. Science China Life Sciences. 60(11). 1203–1213. 9 indexed citations

19.

Wu, Fuquan, Tian Fang, Le‐Xing Yu, et al.. (2016). ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. Journal of Hepatology. 65(2). 314–324. 179 indexed citations

20.

Ma, Xiaoxin, et al.. (2009). Experimental Research on the Depressant Effect of Aspirin on Ishikawa Adenocarcinoma Endometrium Cell Growth. International Journal of Gynecological Cancer. 19(7). 1182–1185. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact